Staphylococcus aureus USA300 MRSA (BAA-1717), Wound Infection Model, CFU Data
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This assay assesses the antimicrobial efficacy of test articles in an excisional wound infection model with a community acquired MRSA. USA300 S. aureus is a community-associated epidemic MRSA that causes rapidly progressive and fatal diseases. This strain, originally named TCH1516, is resistant to erythromycin and most classes of beta-lactam antibiotics. It is susceptible to quinolones, vancomycin, daptomycin, linezolid, and carbapenems.
SPECIES
Staphylococcus aureus
ORGANISM
Gram-positive Bacteria
INCUBATION CONDITIONS
Aerobic
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 immune competent mice are used. Animals are anesthetized, shaved, and a wound is generated with a sharp punch (ID 12 mm) then inoculated with S. aureus culture. Test substance and vehicle are administered at time intervals after infection. Doses may also be administered topically or by IV, SC, PO, IM, IP or IV infusion. The animals are euthanized by carbon dioxide asphyxiation at specified time intervals after treatment initiation (24 hr to two weeks), the wound is excised and microbial counts in the wound tissue is enumerated. Pathogen counts from treatment groups are compared to vehicle groups and the signficance of an effect is determined.
CRITERIA FOR SIGNIFICANCE
Significant difference is determined at ≥ 2-log or P < 0.05
TURNAROUND TIME
STANDARD
25 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences